Lasmiditan (withdrawn)
Evidence-based neurology checklist on lasmiditan (withdrawn): Pharmacology Lasmiditan is a serotonin 1F receptor agonist It belongs to the Ditan drug family It is suitable for patients with cardiovascular risks: it does not cause vasoconstriction Dosing Contraindications and precautions Side effects
Pharmacology
- Lasmiditan is a serotonin 1F receptor agonist
- It belongs to the Ditan drug family
- It is suitable for patients with cardiovascular risks: it does not cause vasoconstriction
Dosing
Contraindications and precautions
Side effects
References
- Raffaelli B, Israel H, Neeb L, Reuter U. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother 2017; 18:1409-1415.
- Lamb YN. Lasmiditan: first approval. Drugs 2019; 79:1989-1996.
- Krege JH, Rizzoli PB, Liffick E, et al. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia 2019; 39:957-966.
- Brandes JL, Klise S, Krege JH, et al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 2019; 39:1343-1357.
- Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 2019; 142:1894-1904.
